The corresponding relative hazard reduction is very depending on the tumor biology than over the nodal position and extent of disease [sixty two].g., PARP inhibitor) like a consequence of data on the use of PARP inhibitors in BRCA1/two mutation carriers with advanced breast cancer (LoE 1b/GR B/In the past+) [six] (see also the chapter on treatment